UPDATE 1-Bristol immunotherapy prolongs survival in melanoma trial
June 24, 2014 at 17:55 PM EDT
June 24 (Reuters) - A late-stage trial testing Bristol-Myers Squibb Co's cancer immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival, the company said on Tuesday.